Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study.
Saved in:
| Title: | Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study. |
|---|---|
| Authors: | Pelletier M; Novartis (United States) Cambridge, MA United States., Yang J; Novartis Institutes for BioMedical Research Switzerland., Joshi M; Novartis Institutes for BioMedical Research Cambridge, MA United States., Grauel A; Novartis Institutes for Biomedical Research Cambridge United States., Abecunas C; Novartis Institutes for BioMedical Research, Cambridge, MA, USA United States., Altzerinakou MA; Novartis Institutes for BioMedical Research Switzerland., Zhou Z; Novartis Institutes for BioMedical Research, Shanghai, China China., Zhu X; Novartis Institutes for BioMedical Research Cambridge, MA United States., Clark K; Novartis Institutes for BioMedical Research, East Hanover, NJ, USA United States., Li L; Novartis Biomedical Research East Hanover, NJ United States., Bai LY; China Medical University Hospital Taichung Taiwan., Milella M; University of Verona, Verona, Italy Verona, Veneto Italy., Mercade TM; Vall d'Hebron Institute of Oncology Spain., Tai WMD; National Cancer Centre Singapore Singapore Singapore., Bockorny B; Beth Israel Deaconess Medical Center Boston, MA United States., Grell P; Masaryk Memorial Cancer Institute Czech Republic., Sivakumar S; University of Birmingham., Wong MK; Westmead Hospital Australia., Chee CE; National University Hospital Singapore, N/A = Not Applicable Singapore., Aparicio T; Hôpital Saint-Louis Paris France., Prager G; Medical University of Vienna Vienna Austria., Bostel G; Novartis Institutes for BioMedical Research, Cambridge, MA United States., Schiessl B; Novartis Institutes for BioMedical Research, Cambridge, MA United States., Maacke H; Novartis Institutes for BioMedical Research, Cambridge, MA Basel Switzerland., Dranoff G; Dana-Farber Cancer Institute Boston, Massachusetts United States., Shaw A; Dana-Farber Cancer Institute Boston, MA United States., Fabre C; Dana-Farber Cancer Institute Boston United States., Mataraza J; Novartis Institutes for BioMedical Research, Cambridge, MA Cambridge United States., Malek S; Genentech South San Francisco, CA United States., Cremasco V; Novartis Institutes for Biomedical Research Cambridge, MA United States. |
| Source: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2026 Jun 25. Date of Electronic Publication: 2026 Jun 25. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
